Cameron Freeman
Medical · Twin Falls, IDNPI 1174860878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 50.1% of the total. Among medical clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$370
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$219
- Corcept Therapeutics$181
- Novo Nordisk$97
- E.r. Squibb & Sons, L.L.C.$97
- plus $773 from 22 others
What the payments were for
- Food & beverage$3,45399%
- Other$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $1,744 |
| AstraZeneca | 23 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $219 |
| Corcept Therapeutics | 10 | $181 |
| Novo Nordisk | 6 | $97 |
| E.r. Squibb & Sons, L.L.C. | 4 | $97 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Exact Sciences | 4 | $79 |
| Lilly USA, LLC | 6 | $76 |
| Bayer | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Alkermes, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Welch Allyn | 1 | $29 |
| Pfizer | 2 | $27 |
| Boston Scientific | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Merck | 1 | $12 |
| Athena Bioscience, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,481 in reported general payments places this provider in the 90th percentile of 265 medical providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 44 | $60,825 |
| OzempicSemaglutide | 48 | $49,609 |
| FarxigaDapagliflozin Propanediol | 41 | $36,580 |
| TrulicityDulaglutide | 27 | $28,379 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $23,442 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $22,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,956 |
| JardianceEmpagliflozin | 12 | $10,056 |
| MyrbetriqMirabegron | 13 | $5,646 |
| ViibrydVilazodone Hcl | 13 | $4,549 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,650 |
| Buprenorphine Hcl | 17 | $2,570 |
| Gabapentin | 109 | $2,124 |
| Celecoxib | 28 | $1,677 |
| Pregabalin | 27 | $932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $1,744 | $65,37557 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $370 | $60,02378 claims |
| Novo NordiskOzempic | $97 | $49,60948 claims |
| Lilly USA, LLCTrulicity | $76 | $28,37927 claims |
| GSKTrelegy Ellipta | $16 | $19,95620 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $5,64613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 medical providers in Idaho.
Other medical in Twin Falls
- Michael WucinichTwin Falls$8K
- Johnny UrrutiaTwin Falls$2K
- Brett ZundelTerreton$71K
- Jessica BishopBoise$60K
- Kyle GeorgeMeridian$19K
- Jed BartschiIdaho Falls$11K
- Dallin GamblesRexburg$10K
- Cali BradberryBoise$9K
- Weldon RichardsonIdaho Falls$8K
- Wade ChristensenIdaho Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.